AR116548A1 - Anticuerpos contra bcma soluble - Google Patents
Anticuerpos contra bcma solubleInfo
- Publication number
- AR116548A1 AR116548A1 ARP190102761A ARP190102761A AR116548A1 AR 116548 A1 AR116548 A1 AR 116548A1 AR P190102761 A ARP190102761 A AR P190102761A AR P190102761 A ARP190102761 A AR P190102761A AR 116548 A1 AR116548 A1 AR 116548A1
- Authority
- AR
- Argentina
- Prior art keywords
- sbcma
- monoclonal antibody
- multiple myeloma
- binding
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a anticuerpos que se unen a BCMA soluble (sBCMA). Además, la presente se refiere a un sistema de detección que comprende dichos anticuerpos. Los anticuerpos o el sistema de detección pueden usarse para detectar o cuantificar sBCMA, para diagnosticar una enfermedad asociada con sBCMA, para estratificar pacientes, monitorizar la progresión de la enfermedad y evaluar la respuesta terapéutica. Reivindicación 1: Un anticuerpo monoclonal que se une a BCMA soluble (sBCMA), donde la unión del anticuerpo a sBCMA se produce en presencia de un segundo anticuerpo monoclonal que se une a sBCMA. Reivindicación 2: El anticuerpo monoclonal de acuerdo con la reivindicación 1, donde sBCMA tiene la secuencia de aminoácidos tal como se representa en la SEQ ID Nº 34. Reivindicación 14: Un proceso para producir un anticuerpo monoclonal tal como se define en una cualquiera de las reivindicaciones 1 a 10, comprendiendo dicho proceso cultivar una célula huésped tal como se define en la reivindicación 13, en condiciones que permitan la expresión de dicho anticuerpo monoclonal y recuperar el anticuerpo monoclonal producido del cultivo. Reivindicación 15: Una composición que comprende un anticuerpo monoclonal tal como se define en una cualquiera de las reivindicaciones 1 a 10, o producido según el proceso de la reivindicación 14. Reivindicación 16: Un sistema de detección que comprende a) un primer anticuerpo monoclonal que se une a sBCMA, y b) un segundo anticuerpo monoclonal que se une a sBCMA, donde la unión del primer anticuerpo monoclonal a sBCMA se produce en presencia del segundo anticuerpo monoclonal que se une a sBCMA, y/o donde la unión del segundo anticuerpo monoclonal a sBCMA se produce en presencia del primer anticuerpo monoclonal que se une a sBCMA. Reivindicación 31: El uso de una cualquiera de las reivindicaciones 25, 29 ó 30 o el método de una cualquiera de las reivindicaciones 26 - 30, donde la enfermedad se selecciona del grupo que consiste en mieloma múltiple, mieloma múltiple recidivante y/o refractario, mieloma múltiple de cadena pesada, mieloma múltiple de cadena ligera, mieloma extramedular (plasmacitoma extramedular, mieloma múltiple extramedular), plasmacitoma, leucemia de células plasmáticas, macroglobulinemia de Waldenström (linfoma linfoplasmacítico), mieloma latente (mieloma múltiple latente), leucemia linfocítica crónica (CLL), linfoma primario del SNC (PCNSL), y linfoma no Hodgkin de linfocitos B (B-NHL).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738997P | 2018-09-28 | 2018-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR116548A1 true AR116548A1 (es) | 2021-05-19 |
Family
ID=68296657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102761A AR116548A1 (es) | 2018-09-28 | 2019-09-27 | Anticuerpos contra bcma soluble |
Country Status (11)
Country | Link |
---|---|
US (1) | US11505614B2 (es) |
EP (1) | EP3856781A1 (es) |
JP (1) | JP2022501389A (es) |
KR (1) | KR20210068408A (es) |
CN (1) | CN112703204A (es) |
AR (1) | AR116548A1 (es) |
BR (1) | BR112021005669A2 (es) |
MA (1) | MA53732A (es) |
TW (1) | TW202028239A (es) |
UY (1) | UY38393A (es) |
WO (1) | WO2020069303A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3819007B1 (en) * | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
WO2024098026A2 (en) * | 2022-11-04 | 2024-05-10 | Mink Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
WO2024168192A1 (en) * | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1985A (en) | 1841-02-18 | Charles m | ||
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
ES2142801T3 (es) | 1991-03-11 | 2000-05-01 | Univ Georgia Res Found | Clonacion y expresion de luciferasa de renilla. |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
EP0759170B1 (en) | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
US6458547B1 (en) | 1996-12-12 | 2002-10-01 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
AU765703B2 (en) | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
WO2000006605A2 (en) | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominibodies |
KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
ES2432792T5 (es) | 2007-04-03 | 2023-01-16 | Amgen Res Munich Gmbh | Dominio de unión a CD3-épsilon específico de especies cruzadas |
AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
EA028220B1 (ru) * | 2011-05-27 | 2017-10-31 | Глаксо Груп Лимитед | Иммуноконъюгат на основе белка, связывающегося с bcma (cd269/tnfrsf17), его медицинское применение и фармацевтическая композиция |
WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
EP3029068A1 (en) * | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
AU2016353067B2 (en) | 2015-11-13 | 2023-10-05 | Sanford Research | Anti-BCMA polypeptides and proteins |
EP4079320A1 (en) * | 2016-01-12 | 2022-10-26 | Inc. Oncotracker | Improved methods for monitoring immune status of a subject |
CR20180420A (es) | 2016-02-03 | 2018-12-05 | Amgen Inc | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t |
-
2019
- 2019-09-27 CN CN201980056983.1A patent/CN112703204A/zh active Pending
- 2019-09-27 TW TW108135221A patent/TW202028239A/zh unknown
- 2019-09-27 MA MA053732A patent/MA53732A/fr unknown
- 2019-09-27 UY UY0001038393A patent/UY38393A/es not_active Application Discontinuation
- 2019-09-27 US US16/585,318 patent/US11505614B2/en active Active
- 2019-09-27 JP JP2021516763A patent/JP2022501389A/ja active Pending
- 2019-09-27 AR ARP190102761A patent/AR116548A1/es unknown
- 2019-09-27 EP EP19790922.9A patent/EP3856781A1/en active Pending
- 2019-09-27 BR BR112021005669-6A patent/BR112021005669A2/pt unknown
- 2019-09-27 WO PCT/US2019/053433 patent/WO2020069303A1/en active Search and Examination
- 2019-09-27 KR KR1020217008023A patent/KR20210068408A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
CN112703204A (zh) | 2021-04-23 |
TW202028239A (zh) | 2020-08-01 |
KR20210068408A (ko) | 2021-06-09 |
MA53732A (fr) | 2022-01-05 |
WO2020069303A1 (en) | 2020-04-02 |
US20200102398A1 (en) | 2020-04-02 |
BR112021005669A2 (pt) | 2021-06-22 |
EP3856781A1 (en) | 2021-08-04 |
JP2022501389A (ja) | 2022-01-06 |
UY38393A (es) | 2020-03-31 |
US11505614B2 (en) | 2022-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR116548A1 (es) | Anticuerpos contra bcma soluble | |
Koutsakos et al. | Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity | |
PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
PE20241349A1 (es) | Anticuerpos de union a cd3 | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
AU2018258190A1 (en) | Methods and apparatus that increase sequencing-by-binding efficiency | |
EA201692157A1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
JP2016026303A5 (es) | ||
BR112017003582A2 (pt) | anticorpos, composições e usos | |
PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
AR106188A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
RU2010133547A (ru) | Анти-cldn антитела | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
AR090410A1 (es) | Anticuerpos mutantes y conjugacion de los mismos | |
HRP20211541T1 (hr) | Anti-asic1 antitijela i njihove upotrebe | |
AR115419A1 (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecifícos y sus usos | |
AU2018274704A1 (en) | Assay for plasma cell associated disease | |
WO2018167141A3 (en) | Target detection using a monovalent antibody | |
AR109857A1 (es) | Anticuerpos anti-chikv y usos de éstos | |
CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
ZA202205383B (en) | Novel anti-nogo-a antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |